Previous 10 | Next 10 |
SilverBow Resorces Inc. (SBOW) is expected to report $2.36 for Q4 2023 FAT Brands Inc. Class B Common Stock (FATBB) is expected to report for quarter end 2023-12-31 Ecovyst Inc. (ECVT) is expected to report $0.2 for Q4 2023 MYR Group Inc. (MYRG) is expected to report $1.41 for Q4 2023...
CAMBRIDGE, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on Wednesday, February 28, 2024, at 8:00 a.m. ET to discuss results for the fourth quarter and full ye...
2024-02-13 13:14:10 ET Editas Medicine, Inc. (EDIT) Oppenheimer 34th Annual Healthcare Life Sciences Conference February 13, 2024 08:40 AM ET Company Participants Dr. Baisong Mei - Senior Vice President and Chief Medical Officer Conference Call Participants J...
2024-02-08 21:37:41 ET Summary Intellia is adopting a distinct strategy by focusing on in-vivo gene editing, potentially redefining industry standards and expectations. Interim results from Intellia's in-vivo gene-editing program for ATTR amyloidosis show promising safety and effi...
2024-02-07 14:00:23 ET Editas Medicine, Inc. (EDIT) Guggenheim 6th Annual Biotechnology Conference February 07, 2024 09:30 AM ET Company Participants Gilmore O'Neill - President and CEO Conference Call Participants Debjit Chattopadhyay - Guggenheim Pres...
2024-01-29 06:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-28 08:45:00 ET What's the appeal of investing in relatively small and little-known corporations? Though these businesses come with heightened risks, getting in on the ground floor can potentially be lucrative over the long run if they become successful. Just think: What if you had i...
2024-01-25 10:57:50 ET Summary More than one year into the Launch of Zynteglo and Skysona, BLUE's sales remain underwhelming. The company launched a third gene therapy, Lyfgenia, but faces similar commercialization challenges. High treatment costs, limited patient base, outsou...
2024-01-25 08:00:00 ET Summary Alex Carchidi calls the biotech sector highly risky and speculative, and says diversification is key for investors. Funding is currently difficult to obtain in the biotech industry, but a turnaround is expected. Competitive stories in gene editin...
2024-01-21 09:37:00 ET Editas Medicine (NASDAQ: EDIT) and CRISPR Therapeutics (NASDAQ: CRSP) share more than a few similarities despite being at different stages of the biotech lifecycle. Both companies are betting that their acumen with gene editing will enable them to make...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today announced...
CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that three abstracts have been accepted for presentation, including one oral presentation, at the 27 th Annual Meeting of the American Society of G...
2024-04-21 00:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...